Ozempic’s early success in kidney disease trial hits dialysis stocks – Yahoo Finance

by

  1. Ozempic’s early success in kidney disease trial hits dialysis stocks Yahoo Finance
  2. Novo Nordisk stops Ozempic kidney trial after early signs of success Reuters
  3. Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit STAT
  4. Dialysis Providers’ Stocks Drop as Novo Nordisk (NYSE:NVO) Halts Ozempic Study – TipRanks.com TipRanks
  5. Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis GlobeNewswire
  6. View Full Coverage on Google News

Read original article here

Leave a Comment